Inventiva SACA

Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report

14 Oct 2024 01:35:00 By Nasdaq GlobeNewswire

Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study

14 Oct 2024 01:30:00 By Nasdaq GlobeNewswire

Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results

25 Sep 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva Reports Preliminary 2024 First-Half Financial Information¹

31 Jul 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor

25 Jul 2024 15:00:00 By Nasdaq GlobeNewswire

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

19 Jul 2024 10:30:00 By Nasdaq GlobeNewswire

Inventiva announces a €20.1 million issuance of royalty certificates

18 Jul 2024 01:30:00 By Nasdaq GlobeNewswire

Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position  

05 Jul 2024 15:00:00 By Nasdaq GlobeNewswire

Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024  

21 Jun 2024 15:05:00 By Nasdaq GlobeNewswire

Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024  

21 Jun 2024 15:00:00 By Nasdaq GlobeNewswire

Combined General Meeting of June 20, 2024 - Availability of the preparatory documents

30 May 2024 01:30:00 By Nasdaq GlobeNewswire

Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024

30 May 2024 01:30:00 By Nasdaq GlobeNewswire

Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

22 May 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

21 May 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH

16 May 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor

13 May 2024 01:30:00 By Nasdaq GlobeNewswire

Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

03 Apr 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces the nomination of Andre Turenne as Director

28 Mar 2024 02:00:00 By Nasdaq GlobeNewswire

Inventiva reports its 2023 full-year results

27 Mar 2024 15:00:00 By Nasdaq GlobeNewswire

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

22 Mar 2024 15:00:00 By Nasdaq GlobeNewswire